Minerva Neurosciences, Inc (NASDAQ:NERV) Given Average Rating of “Reduce” by Analysts

Minerva Neurosciences, Inc (NASDAQ:NERV) has been given a consensus rating of “Reduce” by the four analysts that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $10.3333.

A number of equities analysts have weighed in on NERV shares. Zacks Research downgraded shares of Minerva Neurosciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Wednesday, June 24th. Wall Street Zen raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Jefferies Financial Group upgraded shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating and boosted their price objective for the stock from $7.50 to $10.00 in a research report on Friday, August 14th.

Minerva Neurosciences Stock Performance

Shares of NASDAQ:NERV opened at $4.43 on Tuesday. Minerva Neurosciences has a twelve month low of $1.93 and a twelve month high of $12.46. The firm has a market cap of $211.53 million, a PE ratio of -0.15 and a beta of -0.08. The business has a fifty day moving average of $4.52 and a 200-day moving average of $5.38.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. On average, analysts anticipate that Minerva Neurosciences will post -0.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Minerva Neurosciences

Several large investors have recently made changes to their positions in the company. Vivo Capital LLC bought a new position in Minerva Neurosciences in the fourth quarter valued at about $17,377,000. Janus Henderson Group PLC raised its holdings in Minerva Neurosciences by 47,614.0% during the 1st quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock worth $25,873,000 after purchasing an additional 4,285,259 shares during the last quarter. Federated Hermes Inc. lifted its position in Minerva Neurosciences by 297.5% during the 4th quarter. Federated Hermes Inc. now owns 5,371,775 shares of the biopharmaceutical company’s stock valued at $21,595,000 after purchasing an additional 4,020,500 shares during the period. Logos Global Management LP acquired a new position in Minerva Neurosciences during the 4th quarter valued at about $13,310,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in shares of Minerva Neurosciences in the 4th quarter valued at about $11,409,000. Institutional investors and hedge funds own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.